We have developed a micro-extraction procedure for the analysis of chlordiazepoxide and its two unique metabolites, demoxepam and desmethylchlordiazepoxide, in plasma, using liquid chromatography. The method is both reliable and sensitive for the quantitation of low plasma concentrations of these three compounds. The extraction procedure allows rapid sample processing, which, together with the small sample volume (100 ilL), makes it ideal for routine sample handling. The limit of detection for the three compounds ranged from 0·075 to 0·125 mg/L and recovery of the three different benzodiazepines ranged from 87 to 94%. Within-and between-assay coefficients of variation ranged from 3·1--4·5% and from 4·7 to 7·6%, respectively.
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Chlordiazepoxide (Librium) is used in the management of alcohol withdrawal and patient compliance may be investigated using measurements of plasma chlordiazepoxide concentration.
Chlordiazepoxide is metabolized initially by N-demethylation to desmethylchlordiazepoxide, followed by deamination to demoxepam; both of these metabolites are unique to chlordiazepoxide. Further metabolism to desmethyldiazepam (nordiazepam) and oxazepam then occurs. ' Although several different methods have been reported for determining benzodiazepine concentrations in plasma and urine, difficulties have been encountered in the simultaneous detection of chlordiazepoxide and its major metabolites. Chlordiazepoxide is difficult to assay by gas chromatography as it is thermally unstable, as is demoxepam, which is converted to desmethyldiazepam. Chlordiazepoxide and its metabolites have been measured using reverse-phase liquid chromatography (LC). The early methods suffered from poor resolution, low recovery Correspondence: D J Garretty. 528 and unacceptably long retention times. Later methods required large sample volumes and/or lengthy sample preparation, often with acid hydrolysis.s ! We report here a method capable of detecting chlordiazepoxide, demoxepam and desmethylchlordiazepoxide in small volumes of plasma. 
MATERIALS AND METHODS

Reagents and standards
Standard solutions
Standards were prepared in methanol using hydrochlorides of chlordiazepoxide and desmethylchlordiazepoxide, and the free base of dernoxepam. Stability studies showed that methanolic and plasma solutions containing all three compounds could be stored at -20 DC for a period of 6 months without any significant loss (unpublished data).
A calibration standard containing chlordiazepoxide 3 mg/L, demoxepam 2 mg/L and desmethylchlordiazepoxide 4 mg/L was prepared using drug-free plasma. This was chromatographed every 10 patients' samples to compensate for any drift in the LC system. Aliquots of this standard were stored at -20 DC until required for analysis, and were stable for 6 months.
Extraction procedure Plasma samples for analysis were brought to room temperature, mixed and centrifuged at room temperature for 5 min (1000 g). Aliquots (100 ilL) of plasma were then added to 50 ilL of internal standard (5 mg/L bromazepam in methanol) and 50 ilL of carbonate buffer (I M, pH 10) in acid-washed glass Dreyer?' tubes (Merck Ltd, BDH Laboratory Supplies, Poole, UK). N-butylacetate (200 ilL) was added, and the tube contents were mixed and centrifuged. The n-butylacetate (upper) layer was aspirated and a second extraction was performed with a further 200 ilL of n-butylacetate. The upper layer of this mixture was evaporated to dryness under nitrogen at 85"C. Extracts were reconstituted in methanol (200 ilL) and either stored at~20 DC or analysed immediately.
Liquid chromatography
Forty microlitres of each plasma extract was injected onto a 25 x 0-4cm (i.d.) Hichrom'" C 1S -RPB (reverse-phase base deactivated) column with 5 11m particle size (Hichrom Ltd, Reading, UK), protected by a 5 x 0-46 ern (i.d.) guard column packed with Bondapak'" C1s-Corasil material (5 11m particle size; Waters Chromatography Division, Millipore [UK] Ltd, Harrow, UK). A Gilson'" 40lC dilutor, 307 piston pump, 118 UV/Vis detector (9 nm band width, 5 mm light path, 10 ilL cell volume, wavelength 241 nm), 231 XL sampling injector and 715 HPLC system controller were used for chromatographic analysis (Anachem UK Ltd, Luton, UK).
The mo bile phase consisted of deionized water/ methanol/acetonitrile/acetic acid (51:28:16:0'2, v:v; pH 3,7), and was recycled through the LC system at a flow rate of 1·0 mL/min, for up to 1 week (or for 100 injections). Before use, the mobile phase was degassed by vacuum filtration (Waters) using a 0·51lm filter (Millipore Corporation, Harrow, UK). The column was washed after use with methanol/deionized water (80:20, v:v) for 1 h. A weekly wash with chloroform/methanol (20:80, v:v) was performed to prevent accumulation of excess lipid on the column from the plasma extracts.
The retention times (min) were: desmethylchlordiazepoxide (A), 8·70; chlordiazepoxide (B), 10·10; bromazepam (internal standard, C), 11·70; and demoxepam (D), 13·97 ( Fig. I) .
Blood samples were collected from patients (n = 10) attending the Leeds addiction unit. The patients were prescribed chlordiazepoxide alone (n = 4), chlordiazepoxide in conjunction with diazepam and temazepam (n = 1), chlordiazepoxide and nitrazepam (n = 4) and chlordiazepoxide and temazepam (n = 1) (Table I) .
Serial samples were obtained from two patients attending the unit on a daily basis. One patient was prescribed reducing doses of chlordiazepoxide for alcohol detoxification, from 140mg/day to IOrng/day over a 10-day period. The second patient was prescribed chlordiazepoxide (40mg/day for 6 days and 20 mg/day for days 7 and 8) and nitrazepam whilst following an opioid detoxification regime.
For all patients, blood samples were collected approximately 12 h after the last dose.
RESULTS
Linearity was assessed by measuring plasma to which known amounts of the compounds had been added. The method was linear over the following concentration ranges: chlordiazepoxide hydrochloride, 0,125-10·0 mg/L; demoxepam, 0·125--4·0 mg/L; and desmethylchlordiazepoxide hydrochloride, 0·125-16·0 mg/L, A quality control (Qq sample was prepared by pooling plasma from patients who had been prescribed chlordiazepoxide. This was stored at -20 DC and was found to be stable for 6 months. Within-batch CVs (n = 10) were: chlordiazepoxide, 4'5%; dernoxepam, 3·1%; and desmethylchlordiazepoxide, 3·2%. The between-batch CVs were: chlordiazepoxide, 5·8%; demoxepam, 7·6%; and desmethylchlordiazepoxide, 4·7%. The analytical recoveries calculated by comparing QC samples with equivalent methanolic standards (n = 10) were: chlordiazepoxide, 94%; dernoxepam, 87%; and desmethylchlordiazepoxide, 87%.
The lowest quantities which could be detected by LC (signal:noise ratio of 3) were 0·075 rng/L chlordiazepoxide hydrochloride, 0·125 mg/L dernoxepam and 0·08 rng/L desmethylchlordiazepoxide hydrochloride.
Plasma obtained from drug-free volunteers did not show any interference from endogenous compounds. We injected methanolic standards (I mg/L) and extracts of plasma containing a known quantity (1 mg/L) of a range of drugs onto the LC column. None of the drugs tested interfered with the assay ( Table 2) .
As polyethylene glycol (PEG, a macrogol included in capsule preparations of temazepam) has been shown to interfere with some chromatographic analyses," plasma samples containing PEG (200 mg/L, molecular weights 600, 1500 and 6000) were analysed and no interference was detected. No carry-over effect was noted from late-eluting benzodiazepines (nitrazeparn, temazepam and diazepam). Table I shows the plasma concentrations of chlordiazepoxide, demoxepam and desmethylchlordiazepoxide, 12 h after the last dose in 10 patients who were on different doses of chlordiazepoxide. Chlordiazepoxide and desmethylchlordiazepoxide were detected in all samples, whereas dernoxepam was detected in only eight. Desmethyldiazepam and oxazepam (metabolites of chlordiazepoxide) were not detected in any of the samples.
Chlordiazepoxide, desmethylchlordiazepoxide and demoxepam were detected in all samples obtained from the patient on an alcohol detoxification regime (Fig. 2) . Plasma chlordiazepoxide and desmethylchlordiazepoxide concentrations were very low in the samples obtained from the patient on an opioid detoxification regime. Demoxepam was detected in the day 4 and day 5 samples. Neither desmethyldiazepam and oxazepam, nor nitrazepam, were detected in any of the plasma samples (Fig. 2 ).
DISCUSSION
Chlordiazepoxide, demoxepam and desmethylchlordiazepoxide are extremely weak bases and, therefore, a strongly acidic, polar eluent is required for maximum retention using reversephase chromatography. When a mobile phase of water/methanol/acetonitrile/acetic acid (51:28: 16:6, v:v, pH 2, 9) , as used in the determination of benzodiazepines in urine, was investigated," chlordiazepoxide and desmethylchlordiazepoxide were found to co-elute and sensitivity was unacceptably low. Increasing the amount of water and reducing the amount of methanol (i.e. increasing the polarity of the mobile phase) led to improved separation of the three compounds, but increased the retention times and reduced the sensitivity. Increasing the pH of the original mobile phase combination to 3,7, however, allowed adequate separation with optimal sensitivity. This mobile phase (51:28:16:0.2, v:v, pH 3, 7) was also found to be suitable for the separation of five additional benzodiazepines: 100 ilL of plasma, 2 x 200 ilL of n-butylacetate and 50 ilL of IM carbonate buffer (pH 10).
Chlordiazepoxide is a long-acting benzodiazepine with an elimination half-life (t,;,{3) ranging from 5 to 30 h (mean, IS h).~Chlordiazepoxide is readily absorbed following oral administration. It is metabolized by demethylation to desmethylchlordiazepoxide (ty,{3 = 14-95 h), which in turn undergoes deamination to demoxepam (t y,{3=40-100h). Hydrolysis and reduction of demoxepam results in the formation of desmethyldiazepam, which then undergoes hydroxylation to oxazepam."
The therapeutic plasma concentration of chlordiazepoxide is usually within the range of 0·4 to 4mgjL. 7 Demoxepam and desmethylchlordiazepoxide will reach steady-state concentrations in plasma after a period of six half-lives, i.e. 3·5 weeks. Demoxepam, however, is not normally detected in plasma after a single dose of chlordiazepoxide." The concentrations of both desmethylchlordiazepoxide and demoxepam contribute to the overall clinical activity of chlordiazepoxide."
We found widely varying concentrations of the three benzodiazepines in the 10 plasma samples analysed (see Table I ). Even when the dose of chlordiazepoxide was reduced from 140mgjd to IlOmgjd, plasma concentrations of chlordiazepoxide and desmethylchlordiazepoxide in the alcohol detoxification patient steadily increased (Fig. 2) . A gradual increase in plasma demoxepam also occurred over the same period. Further dose reductions resulted in falling plasma concentrations of both chlordiazepoxide and desmethylchlordiazepoxide, while the demoxepam concentration rose, reaching a peak on day 5. Plasma chlordiazepoxide concentration was extremely low throughout, with desmethylchlordiazepoxide concentrations showing a gradual increase in the patient undergoing opioid detoxification. Demoxepam was not detected in the plasma until day 4.
These results may reflect differences between individuals in their metabolism of chlordiazepoxide, particularly where a metabolic pathway is shared with other benzodiazepines. Results may also indicate variable compliance. Measurement of plasma chlordiazepoxide as well as the two metabolites may be necessary for a true assessment of dosage in view of the pharmacological activities of demoxepam and desmethylchlordiazepoxide. Measurement of plasma concentrations of all three benzodiazepines is also required for pharmacokinetic studies of nitrazepam, desmethyldiazepam, oxazepam, temazepam and diazepam.
We examined three different benzodiazepines, triazolam, prazepam and bromazepam, as internal standards and found that bromazepam, which is very rarely prescribed, eluted with a retention time of 1\·70 min and did not interfere with any of the other compounds of interest.
Extraction methods for benzodiazepines often involve large sample volumes and lengthy sample preparation, together with acid hydrolysis. In a routine laboratory setting, sample volume and speed of sample analysis are important considerations. To reduce the amount of sample required, small volumes of plasma (100 ilL) and solvent (200 ilL, 300 ilL and 500 ilL) were investigated. Successful extraction of chlordiazepoxide, demoxepam and desmethylchlordiazepoxide was achieved using Expressing plasma concentrations of desmethylchlordiazepoxide and chlordiazepoxide as a ratio may allow differentiation between megadose users/abusers and therapeutic users of chlordiazepoxide. Problems may arise where patient compliance is suspect and/or the dose is not constant. Reducing doses of chlordiazepoxide (alcohol detoxification patient) showed constantly changing desmethylchlordiazepoxide: chlordiazepoxide ratios, rising from 2: I (day 2) to 6:I (day 10). Plasma desmethylchlordiazepoxide and chlordiazepoxide concentrations were very low in the opioid detoxification patient, with ratios ranging from 14:1 (day 2) to 0·5:1 (day 8); the results suggest questionable compliance.
In conclusion, the LC method for measuring chlordiazepoxide is quick, utilizes small quantities of plasma, and is sensitive at low plasma concentrations. The procedure could be used in hospital laboratories, drug treatment agencies and forensic toxicology laboratories.
